Kiora Pharmaceuticals (KPRX) EBT (2016 - 2026)

Kiora Pharmaceuticals (KPRX) has reported EBT for 11 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 8.19% year-over-year to -$2.1 million; the trailing twelve-month figure through Jun 2026 stood at -$12.3 million (down 23.96% YoY), and the FY2025 full-year result was -$12.1 million, down 314.1% from the prior year.
• EBT advanced to -$2.1 million in Q2 2026 per KPRX's latest filing, from -$2.4 million in the prior quarter.
• Across five years, EBT topped out at $13.5 million in Q1 2024 and bottomed at -$7.2 million in Q4 2025.
• Historically, EBT has averaged -$2.0 million across 5 years, with a median of -$2.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT surged 801.91% in 2024, then plunged 232.01% in 2025.
• Over 5 years, EBT stood at -$2.6 million in 2022, then grew by 21.43% to -$2.1 million in 2023, then retreated by 4.12% to -$2.2 million in 2024, then slumped by 232.01% to -$7.2 million in 2025, then soared by 70.99% to -$2.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$2.1 million, -$2.4 million, and -$7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.